Genesis II XLPE Resurfacing Patellar Components

K150241 · Smith & Nephew, Inc. · JWH · Oct 27, 2015 · Orthopedic

Device Facts

• Record ID: K150241
• Device Name: Genesis II XLPE Resurfacing Patellar Components
• Applicant: Smith & Nephew, Inc.
• Product Code: JWH · Orthopedic
• Decision Date: Oct 27, 2015
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 888.3560
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

The Genesis II XLPE Resurfacing Patellar Components are intended to be used with Smith & Nephew Total Knee Systems and Patello-Femoral Replacement Knee Systems and their cleared Indications for Use. Indications for Total Knee Replacement 1. Rheumatoid arthritis. 2. Post-traumatic arthritis, osteoarthritis, or degenerative arthritis. 3. Failed osteotomies, unicompartmental replacement, or total knee replacement. 4. Posterior stabilized knee systems are designed for use in patients in primary and revision surgery, where the anterior and posterior cruciate ligaments are incompetent and the collateral ligaments remain intact. 5. Constrained knee systems are designed for use in patients in primary and revision surgery, where the posterior cruciate ligament and one or both of the collateral ligaments (i.e. medial collateral collateral ligament) are incomnetent. 6. Hinge knee systems are designed for use in patients in primary and revision surgery, where the posterior cruciate ligament and one or both of the collateral ligaments (i.e. medial collateral collateral ligament) are absent or incompetent. Indications for Patello-Femoral Replacement 1. Degenerative arthritis in the distal femur and patella; 2. A history of patellar dislocation or patellar fracture; and 3. Failed previous surgery (arthroplasty, tibial tubercle elevation, lateral release) where pain, deformity or dysfunction persists. The Smith & Nephew Patello-Femoral Implants are intended for implantation with bone cement.

Device Story

Genesis II XLPE Resurfacing Patellar Components are orthopedic implants used in total knee or patello-femoral replacement surgeries. Manufactured from highly cross-linked polyethylene (7.5 Mrad XLPE), these round or oval components replace the articulating surface of the patella. The device is implanted by a surgeon using bone cement to secure the component to the patella. It functions as a bearing surface within the knee joint, articulating against the femoral component of the knee system. By providing a durable, low-wear surface, the device aims to restore joint function, reduce pain, and improve mobility in patients with degenerative or post-traumatic joint disease. The device is intended for single use.

Clinical Evidence

No clinical data provided. Substantial equivalence is supported by non-clinical bench testing, specifically static shear testing and fatigue shear testing, to validate the performance of the highly cross-linked polyethylene material.

Technological Characteristics

Material: 7.5 Mrad highly cross-linked polyethylene (XLPE). Form factor: Round and oval resurfacing patellar components. Principle: Cemented, single-use orthopedic bearing surface. Connectivity: None. Sterilization: Not specified.

Indications for Use

Indicated for patients requiring total knee or patello-femoral replacement due to rheumatoid, post-traumatic, or degenerative arthritis; failed previous knee surgeries; patellar dislocation; or patellar fracture. Contraindicated where collateral ligaments are absent or incompetent (unless using specific constrained/hinge systems).

Regulatory Classification

Identification

A knee joint patellofemorotibial polymer/metal/polymer semi-constrained cemented prosthesis is a device intended to be implanted to replace a knee joint. The device limits translation and rotation in one or more planes via the geometry of its articulating surfaces. It has no linkage across-the-joint. This generic type of device includes prostheses that have a femoral component made of alloys, such as cobalt-chromium-molybdenum, and a tibial component or components and a retropatellar resurfacing component made of ultra-high molecular weight polyethylene. This generic type of device is limited to those prostheses intended for use with bone cement (§ 888.3027).

Predicate Devices

• Genesis II Knee System (K951987)
• Anthem Total Knee System (K142807)

Reference Devices

• Competitor PFJ Patella-Femoral Knee Implants (K051086)
• Legion Hinge Knee System (K081111)
• Genesis II Constrained System (K962137)
• Reference Predicate (K071071)

Submission Summary (Full Text)

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a circular seal with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is a stylized image of three human profiles facing to the right, stacked on top of each other.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

October 28, 2015

Smith & Nephew, Incorporated Allison Chan Regulatory Affairs Specialist 7135 Goodlett Farms Parkways Cordova, Tennessee 38018

Re: K150241

Trade/Device Name: Genesis II XLPE Resurfacing Patellar Components Regulation Number: 21 CFR 888.3560 Regulation Name: Knee joint patellofemorotibial polymer semi-constrained cemented prosthesis Regulatory Class: Class II Product Code: JWH, MBH, KRO, KRR Dated: September 25, 2015 Received: September 28, 2015

Dear Ms.Chan:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. Iisting of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set

{1}------------------------------------------------

forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number [phone] or [phone] or at its Internet address

http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number [phone] or [phone] or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

# Mark N. Melkerson -S

Mark N. Melkerson Director Division of Orthopedic Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

Form Approved: OMB No. 0910-0120

Expiration Date: January 31, 2017

See PRA Statement below.

#### DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration

#### Indications for Use

510(k) Number (if known) K150241

Device Name

Genesis II XLPE Resurfacing Patellar Components

Indications for Use (Describe)

The Genesis II XLPE Resurfacing Patellar Components are intended to be used with Smith & Nephew Total Knee Systems and Patello-Femoral Replacement Knee Systems and their cleared Indications for Use.

Indications for Total Knee Replacement

1. Rheumatoid arthritis.

2. Post-traumatic arthritis, osteoarthritis, or degenerative arthritis.

3. Failed osteotomies, unicompartmental replacement, or total knee replacement.

4. Posterior stabilized knee systems are designed for use in patients in primary and revision surgery, where the anterior and posterior cruciate ligaments are incompetent and the collateral ligaments remain intact.

5. Constrained knee systems are designed for use in patients in primary and revision surgery, where the posterior cruciate ligament and one or both of the collateral ligaments (i.e. medial collateral collateral ligament) are incomnetent.

6. Hinge knee systems are designed for use in patients in primary and revision surgery, where the posterior cruciate ligament and one or both of the collateral ligaments (i.e. medial collateral collateral ligament) are absent or incompetent.

Indications for Patello-Femoral Replacement

1. Degenerative arthritis in the distal femur and patella;

2. A history of patellar dislocation or patellar fracture; and

3. Failed previous surgery (arthroplasty, tibial tubercle elevation, lateral release) where pain, deformity or dysfunction persists.

The Smith & Nephew Patello-Femoral Implants are intended for implantation with bone cement.

Type of Use (Select one or both, as applicable)

X Prescription Use (Part 21 CFR 801 Subpart D)

| Over-The-Counter Use (21 CFR 801 Subpart C)

#### CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

#### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.*

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

> Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

| | 510(k) Summary<br>Genesis II XLPE Resurfacing Patellar Components |
|----------------------------------------------|---------------------------------------------------------------------------------------------------------------|
| Submitted by: | Smith & Nephew, Inc.<br>1450 East Brooks Road<br>Memphis, Tennessee 38116 |
| Date of Summary: | March 25, 2015 |
| Contact Person and Address: | Allison Chan<br>Regulatory Affairs Specialist<br>T 901-399-1098<br>F 901-566-7022 |
| Name of Device: | Genesis II XLPE Resurfacing Patellar Components |
| Common Name: | Knee prosthesis |
| Device Classification Name and<br>Reference: | 21 CFR 888.3560 Knee joint patellofemorotibial<br>metal/polymer/metal semi-constrained cemented<br>prosthesis |
| | 21 CFR 888.3565 Knee joint patellofemorotibial<br>metal/polymer porous-coated uncemented prosthesis |
| | 21 CFR 888.3510 Knee joint femorotibial metal/polymer<br>constrained cemented prosthesis |
| | 21 CFR 888.3540 Knee joint patellofemoral<br>polymer/metal semi-constrained cemented prosthesis |
| Device Class: | Class II |
| Panel Code: | Orthopaedics/87 |
| Product Code: | JWH, MBH, KRO, KRR |

## Device Description

Subject of this Premarket Notification are the Genesis II XLPE resurfacing patellar components manufactured from highly cross linked polyethylene (XLPE) material. The Genesis II XLPE resurfacing patellar components are intended to be used with the following knee systems

- Smith & Nephew Total Knee Systems ●
- Smith & Nephew Patello-Femoral Knee Systems
- Competitor PFJ Patella-Femoral Knee Implants K051086 .
- Legion Hinge Knee System K081111 ●
- Genesis II Constrained System K962137 ●

{4}------------------------------------------------

Components of this premarket notification include

- . Round and Oval Patellar components manufactured from highly cross-linked polyethylene (7.5 Mrad XLPE) material.
## Intended Use

The Genesis II XLPE Resurfacing Patellar Components are intended to be used with Smith & Nephew Total Knee Systems and Patello-Femoral Replacement Knee Systems and their cleared Indications for Use.

## Indications for Total Knee Replacement

- Rheumatoid arthritis. 1.
- Post-traumatic arthritis, osteoarthritis, or degenerative arthritis. 2.
- 3. Failed osteotomies, unicompartmental replacement, or total knee replacement.
- 4. Posterior stabilized knee systems are designed for use in patients in primary and revision surgery, where the anterior and posterior cruciate ligaments are incompetent and the collateral ligaments remain intact.
- 5. Constrained knee systems are designed for use in patients in primary and revision surgery, where the posterior cruciate ligament and one or both of the collateral ligaments (i.e. medial collateral and/or lateral collateral ligament) are incompetent.
- 6. Hinge knee systems are designed for use in patients in primary and revision surgery, where the posterior cruciate ligament and one or both of the collateral ligaments (i.e. medial collateral and/or lateral collateral ligament) are absent or incompetent.

### Indications for Patello-Femoral Replacement

- Degenerative arthritis in the distal femur and patella; 1.
- 2. A history of patellar dislocation or patellar fracture; and
- 3. Failed previous surgery (arthroplasty, tibial tubercle elevation, lateral release) where pain, deformity or dysfunction persists.

The Smith & Nephew Patello-Femoral Implants are intended for implantation with bone cement.

#### Comparison of Technological Characteristics with the Predicate Device

The Genesis II XLPE resurfacing patellar components are substantially equivalent in design and fundamental scientific technology to the defined predicate devices and do not raise any new issues of safety and efficacy. At a high level, the subject and predicate devices are based on the following same technological elements

- . Use only with cement and single use
- Same articular and cement interface geometry .

No technological differences exist between the subject and predicate device.

#### Performance Data

The following performance data were provided in support of the substantial equivalence determination.

{5}------------------------------------------------

# Mechanical Testing

To further support a determination of substantial equivalence, non-clinical bench (mechanical) testing was conducted to support the material change from conventional polyethylene to highly cross linked polyethylene (XLPE) on the Genesis II resurfacing patellar components. Test results demonstrated that the proposed devices are substantially equivalent to the previously cleared predicate device. The specific types of non-clinical testing conducted are listed below.

- Static Shear Testing
- . Fatigue Shear Testing

# Substantial Equivalence Information

The substantial equivalence of the Genesis II XLPE resurfacing patellar components is based on it similarities in the indications for use, design feature, and operational principles to the predicate systems listed in the table below. In addition the change in material to highly crosslinked polyethylene is identical to the material in reference predicate K071071.

| Design Aspect<br>Reviewed | Genesis II XLPE<br>resurfacing patellar<br>components | Genesis II Knee<br>System | Anthem Total<br>Knee System |
|-------------------------------------|-------------------------------------------------------|------------------------------------|------------------------------------|
| 510(k) Number | Subject 510(k) | K951987 | K142807 |
| Predicate Type | Not Applicable | Primary | Primary |
| Manufacturer | Smith & Nephew | Smith & Nephew | Smith & Nephew |
| Similar Indications<br>for Use | Yes | Yes | Yes |
| Similar<br>Sterilization<br>Methods | Yes | Yes | Yes |
| Articulating<br>Surface | Round and oval | Round | Round and oval |
| Material | XLPE | Patellar<br>components -<br>UHMWPE | Patellar<br>components -<br>UHMWPE |

Table 5.1: Substantially Equivalent Primary Predicates to the Genesis II XLPE Resurfacing Patellar Components

# Conclusion

As previously noted, this Traditional 510(k) Premarket Notification is submitted to request clearance for the modified Genesis II XLPE resurfacing patellar components. Based on the similarities to the predicate components and a review of the mechanical testing performed, the devices are substantially equivalent to the above predicate knee systems.